MA50397A - Anticorps anti-tau et leurs utilisations - Google Patents

Anticorps anti-tau et leurs utilisations

Info

Publication number
MA50397A
MA50397A MA050397A MA50397A MA50397A MA 50397 A MA50397 A MA 50397A MA 050397 A MA050397 A MA 050397A MA 50397 A MA50397 A MA 50397A MA 50397 A MA50397 A MA 50397A
Authority
MA
Morocco
Prior art keywords
tau
body anti
Prior art date
Application number
MA050397A
Other languages
English (en)
Inventor
Kishan Agarwala
Shigeru Akasofu
Hirofumi Aoyagi
Silva Hettihewage Alfred Rohan De
Yutaka Hashizume
Malcolm Ian Roberts
Jared Spidel
James Martin Staddon
Original Assignee
Eisai R&D Man Co Ltd
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Ucl Business Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA50397A publication Critical patent/MA50397A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050397A 2017-10-16 2018-10-16 Anticorps anti-tau et leurs utilisations MA50397A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572910P 2017-10-16 2017-10-16
US201762577011P 2017-10-25 2017-10-25
US201862697034P 2018-07-12 2018-07-12

Publications (1)

Publication Number Publication Date
MA50397A true MA50397A (fr) 2020-08-26

Family

ID=64100697

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050397A MA50397A (fr) 2017-10-16 2018-10-16 Anticorps anti-tau et leurs utilisations

Country Status (22)

Country Link
US (4) US10829547B2 (fr)
EP (1) EP3697814A1 (fr)
JP (2) JP6851549B2 (fr)
KR (2) KR20200058480A (fr)
CN (1) CN111630064B (fr)
AU (1) AU2018352308B2 (fr)
BR (1) BR112020007536A2 (fr)
CA (1) CA3077247A1 (fr)
CL (3) CL2020001003A1 (fr)
CO (1) CO2020005981A2 (fr)
IL (2) IL273832B (fr)
JO (1) JOP20200074A1 (fr)
MA (1) MA50397A (fr)
MX (1) MX2020003857A (fr)
NZ (1) NZ762251A (fr)
PE (2) PE20212088A1 (fr)
PH (2) PH12020551216A1 (fr)
SG (1) SG11202003392VA (fr)
TW (3) TWI853617B (fr)
UA (1) UA129617C2 (fr)
WO (1) WO2019077500A1 (fr)
ZA (1) ZA202001548B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
CA3022515A1 (fr) 2016-05-02 2017-11-09 Prothena Biosciences Limited Anticorps reconnaissant tau
CA3022673A1 (fr) 2016-05-02 2017-11-09 Prothena Biosciences Limited Immunotherapie anti-tau
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
NZ762251A (en) * 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
US12060434B2 (en) * 2020-02-25 2024-08-13 Gensun Biopharma Inc. Trispecific T cell engagers
US20220064271A1 (en) * 2020-09-01 2022-03-03 Washington University Methods for treating tauopathies
IL301572A (en) * 2020-10-02 2023-05-01 Lilly Co Eli Methods for reducing the protein content of the host cell in protein purification processes
AU2022307687A1 (en) 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
TW202334201A (zh) 2021-11-03 2023-09-01 日商衛材R&D企管股份有限公司 抗Ｔａｕ抗體之組成物、劑型及方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CA3242280A1 (fr) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Procedes d'utilisation d'un anticorps anti-protofibrille beta-amyloide et d'un anticorps anti-tau
WO2023111618A1 (fr) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Méthodes d'utilisation d'un anticorps anti-amyloïde à protofibrille bêta et d'un anticorps anti-tau
JP2025506389A (ja) 2022-02-02 2025-03-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ｐ－タウ１８１レベルを使用した治療方法
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
CN120202218A (zh) 2022-11-28 2025-06-24 卫材R&D管理有限公司 使用tau PET水平的治疗方法
WO2024254542A1 (fr) 2023-06-09 2024-12-12 Eisai R&D Management Co., Ltd. Procédés de traitement utilisant un anticorps protofibrille anti-abeta
WO2025019457A1 (fr) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Peptides antimicrobiens
WO2025122634A1 (fr) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à la protéine tau
WO2025137359A1 (fr) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Procédés de dosage servant à identifier une maladie
WO2025198916A1 (fr) * 2024-03-16 2025-09-25 Abbvie Inc. Anticorps anti-tau
WO2026015877A1 (fr) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Biomarqueur fluide

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN105732813A (zh) 2007-12-18 2016-07-06 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3239368A1 (fr) 2009-06-10 2010-12-16 New York University Ciblage immunologique de proteines tau pathologiques
PE20140218A1 (es) 2010-10-07 2014-03-01 Ac Inmune S A Composicion farmaceutica
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
CA2829223A1 (fr) 2011-03-11 2012-09-20 Beka Solomon Methode de traitement de tauopathie neurodegenerative
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
PT2794654T (pt) 2011-12-20 2019-09-10 Janssen Biotech Inc Anticorpos anti-phf-tau e suas utilizações
EP2834270B1 (fr) * 2012-04-05 2019-10-30 AC Immune S.A. Anticorps tau humanisé
WO2013177104A2 (fr) 2012-05-21 2013-11-28 Felder Mitchell S Traitement de tauopathies
BR112014029566A2 (pt) 2012-05-31 2017-07-25 Univ Osaka City agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
EP4356927A3 (fr) 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement des formes oligomériques toxiques de tau
WO2014089104A1 (fr) 2012-12-03 2014-06-12 Washington University Procédé de détection d'agrégats dans des échantillons biologiques
HRP20201422T1 (hr) 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
WO2014096321A1 (fr) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps spécifiques de la protéine tau phosphorylée à la sérine 422 et leurs utilisations pour traiter et diagnostiquer les tauopathies
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
LT3007726T (lt) 2013-06-10 2020-09-10 Ipierian, Inc. Tautopatijos gydymo būdai
GB201312226D0 (en) 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
SI3083680T1 (sl) 2013-12-20 2020-06-30 F. Hoffmann-La Roche Ag Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
KR20160138268A (ko) 2014-05-07 2016-12-02 가부시키가이샤 무라타 세이사쿠쇼 탄성표면파 장치
NZ727020A (en) * 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
HRP20210124T1 (hr) * 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
EP3223689A4 (fr) 2014-11-25 2018-05-02 Abbott Diabetes Care Inc. Systèmes de surveillance d'analyte et procédés de surveillance et de test associés
WO2016112078A2 (fr) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anticorps tau/anti-phf et leurs utilisations
EP3261670A4 (fr) * 2015-02-24 2018-08-01 Rpeptide, LLC Anticorps anti-tau
JO3576B1 (ar) * 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
EA037092B1 (ru) 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US9704904B2 (en) * 2015-08-27 2017-07-11 Taiwan Semiconductor Manufacturing Company, Ltd. Deep trench isolation structures and methods of forming same
WO2017062496A2 (fr) 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anticorps anti-sas1b, procédés d'utilisation associés, et compositions et procédés de détection et de traitement du cancer
EP3359569A2 (fr) * 2015-10-06 2018-08-15 Alector LLC Anticorps anti-trem2 et leurs procédés d'utilisation
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3022515A1 (fr) 2016-05-02 2017-11-09 Prothena Biosciences Limited Anticorps reconnaissant tau
KR102551971B1 (ko) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 과인산화된 타우에 특이적인 항체 및 이의 사용 방법
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
KR102784294B1 (ko) * 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof

Also Published As

Publication number Publication date
IL273832B (en) 2022-06-01
US10829547B2 (en) 2020-11-10
TWI853617B (zh) 2024-08-21
CL2021000516A1 (es) 2021-09-24
US20190112364A1 (en) 2019-04-18
PE20210115A1 (es) 2021-01-19
SG11202003392VA (en) 2020-05-28
CL2021000517A1 (es) 2021-09-24
JP2020536534A (ja) 2020-12-17
PH12020551216A1 (en) 2024-06-24
ZA202001548B (en) 2021-10-27
KR20200051035A (ko) 2020-05-12
KR102225178B1 (ko) 2021-03-10
EP3697814A1 (fr) 2020-08-26
CA3077247A1 (fr) 2019-04-25
IL290783A (en) 2022-04-01
BR112020007536A2 (pt) 2020-09-29
NZ762251A (en) 2025-12-19
RU2020115817A3 (fr) 2022-04-08
KR20200058480A (ko) 2020-05-27
US10358485B2 (en) 2019-07-23
PH12020550243A1 (en) 2021-02-15
AU2018352308A1 (en) 2020-03-19
CN111630064A (zh) 2020-09-04
PE20212088A1 (es) 2021-11-04
JP6851549B2 (ja) 2021-03-31
WO2019077500A1 (fr) 2019-04-25
IL273832A (en) 2020-05-31
CN111630064B (zh) 2023-06-27
RU2020115817A (ru) 2021-11-18
TWI809562B (zh) 2023-07-21
CO2020005981A2 (es) 2020-07-31
US20240034777A1 (en) 2024-02-01
JOP20200074A1 (ar) 2020-04-30
MX2020003857A (es) 2021-01-08
US11578120B2 (en) 2023-02-14
TW201927817A (zh) 2019-07-16
AU2018352308B2 (en) 2025-06-05
TW202340244A (zh) 2023-10-16
US20190112365A1 (en) 2019-04-18
US20210024622A1 (en) 2021-01-28
JP7223794B2 (ja) 2023-02-16
UA129617C2 (uk) 2025-06-18
TW202207985A (zh) 2022-03-01
TWI750419B (zh) 2021-12-21
JP2021097698A (ja) 2021-07-01
CL2020001003A1 (es) 2020-10-02

Similar Documents

Publication Publication Date Title
FR24C1023I2 (fr) Anticorps thérapeutiques et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
EP3504243A4 (fr) Anticorps anti-tim-3 et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3661965A4 (fr) Anticorps anti-cd47 et leurs utilisations
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
EP3283516A4 (fr) Anticorps anti-pacap et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
EP3562508A4 (fr) Anticorps anti-lair1 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations